Share this article Share this article ORLANDO, Fla., March 1, 2021 /PRNewswire/ -- AllianceRx Walgreens Prime recently announced results from research analyzing data of females with multiple sclerosis (MS) who became pregnant, and the impact of adherence to their disease-modifying therapies (DMTs) on hospital utilization and cost. Researchers wanted to understand how non-adherence to their DMTs would impact healthcare cost and utilization over a two-year period. The findings suggest for those women continuing their therapy throughout pregnancy, hospitalization costs and use were lower, compared to those who discontinued their therapy. The retrospective study was conducted by Walgreens, in collaboration with AllianceRx Walgreens Prime, a leading specialty and home delivery pharmacy.